摘要
目的:探讨长效β_(2)受体激动剂(LABA)/长效抗胆碱能药物(LAMA)双联支气管扩张剂治疗中重度慢性阻塞性肺疾病(COPD)的效果。方法:选取2023年1月—2024年3月景德镇市第三人民医院收治的100例中重度COPD患者,采用随机数字表法分为两组,各50例。对照组采用布地奈德福莫特罗治疗,观察组加用噻托溴铵治疗。两组均持续治疗2个月。比较两组的临床疗效、COPD评估测试评分表(CAT)评分、改良呼吸困难指数(mMRC)评分、肺功能、血气指标、炎症因子水平。结果:观察组的临床总有效率较对照组高(P<0.05)。治疗后,两组CAT、mMRC评分均较治疗前下降,且观察组较对照组低(P<0.05)。治疗后,两组FEV_(1)、FVC、FEV_(1)/FVC、呼气峰值流速(PEF)均较治疗前升高,吸气阻力较治疗前下降,且观察组较对照组改善更显著(P<0.05)。治疗后,两组PaO_(2)、SaO_(2)均较治疗前升高,PaCO_(2)较治疗前下降,且观察组较对照组改善更显著(P<0.05)。治疗后,两组血清TNF-α、IL-8、IL-6均较治疗前下降,且观察组较对照组低(P<0.05)。结论:LABA/LAMA双联支气管扩张剂治疗中重度COPD,可减轻患者的临床症状,改善肺功能,提高PaCO_(2)、SaO_(2)水平,降低PaO_(2)水平,减少炎症反应,提升疗效。
Objective:To investigate the efficacy of long-acting β_(2)-agonists(LABA)/long-acting muscarinic antagonists(LAMA)dual bronchodilators in the treatment of moderate to severe chronic obstructive pulmonary disease(COPD).Method:A total of 100 patients with moderate to severe COPD admitted to the Third People's Hospital of Jingdezhen City from January 2023 to March 2024 were selected and divided into two groups by random number table method,with 50 cases in each group.The control group was treated with Budesonide and Formoterol Fumarate,and the observation group was treated with Tiotropium Bromide in addition.Both groups were treated continuously for 2 months.The clinical efficacy,COPD assessment test score(CAT)score,modified medical research council(mMRC)score,lung function,blood gas indicators and inflammatory factor levels of the two groups were compared.Result:The total clinical effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the CAT and mMRC scores of both groups decreased compared with those before treatment,and the scores of the observation group were lower than those of the control group(P<0.05).After treatment,FEV_(1),FVC,FEV_(1)/FVC,and peak expiratory flow rate(PEF)in both groups increased compared with those before treatment,inspiratory resistance decreased compared with that before treatment,and the improvement in the observation group were more significant than those in the control group(P<0.05).After treatment,PaO_(2) and SaO_(2) in both groups increased compared with those before treatment,while PaCO_(2) decreased compared with that before treatment,moreover,the improvement in the observation group were more significant than those in the control group(P<0.05).After treatment,the levels of serum TNF-α,IL-8 and IL-6 in both groups decreased compared with those before treatment,and those in the observation group were lower than those in the control group(P<0.05).Conclusion:LABA/LAMA dual bronchodilator therapy can reduce the clinical symptoms of patients with moderate to severe COPD,improve lung function,increase the levels of PaO_(2) and SaO_(2),reduce the level of PaCO_(2),reduce the inflammatory response,and improve the efficacy.
作者
毛景丹
MAO Jingdan(Department of Respiratory and Critical Care Medicine,the Third People's Hospital of Jingdezhen City,Jingdezhen 333000,China)
出处
《中国医学创新》
2025年第22期46-50,共5页
Medical Innovation of China
基金
景德镇市科技计划项目(20201SFZC034)。
关键词
布地奈德福莫特罗
噻托溴铵
慢性阻塞性肺疾病
Budesonide and Formoterol Fumarate
Tiotropium Bromide
Chronic obstructive pulmonary disease
